This is reinforced by prior studies in human primary cells which found that Cas9 RNP delivery did not introduce mutations in p53 or 129 other cancer-related genes (using the Stanford Solid Tumor Actionable Mutation Panel), though at a limit of detection of 5% VAF35,36. The gene discussed is TP53; the disease is neoplasm.